de-Castro-Suárez N, Blanco-Santana R, Cedeño-Arias M, Dávalos-Iglesias JM, Bacallao-Méndez R, Rodríguez-Vera L, Ramos-Suzarte M

Language: Spanish
References: 20
Page: 7-11
PDF size: 334.10 Kb.

ABSTRACT

Introduction: The lack of effective treatment to autosomal dominant polycystic kidney disease (ADPKD) has led researchers to search others alternatives. The evidence from several studies on murine and human models of ADPKD, has demonstrated the significant roll of the epidermal growth factor receptor (EGFR) and the increased receptor tyrosine kinase activity in promoting hyperplasia in cystic epithelia, with formation and growth of resultant renal cysts. The aim of this study was to evaluate the tissue distribution of the EGFR in ADPKD.
Material and methods: Renal biopsies of four patients with ADPKD and two of normal kidney in formalin-fixed, paraffin embedded samples were studied by immunohistochemistry using murine monoclonal antibody (mAb) ior egf/r3 to detect the EGFR. In normal kidney no reactivity of this mAb was observed. In contrast, in specimens of ADPKD, the EGFR was increased and located on apical cystic cells surface.
Results: No reactivity was observed with this mAb in the samples of normal tissue; however, in the samples ADPKD, EGFR was increased and localized in the apical surface of the cystic cells.
Conclusions: These results support a meaningful role for the EGFR in the development of ADPKD. Furthermore, they made it possible to design a phase I clinical trial with mAb nimotuzumab (humanized version of ior egf/r3) in patients with this pathology.

REFERENCES

1. Rossetti S, Consugar MB, Chapman AB. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007; 18: 2143-2160.

2. Wilson PD. Mechanisms of disease: Polycystic Kidney Disease.N Engl J Med. 2004; 350:151-64.

3. Chang Ming-Yang, Ong ACM. Autosomal Dominant Polycystic Kidney Disease: Recent Advances in Pathogenesis and Treatment. Nephron Physiol 2008; 108:p1–p7. abstract

4. Richards WG, Sweeney WE, Yoder BK, Wilkinson JE, Woychik RP et al. Epidermal Growth Factor Receptor Activity Mediates Renal Cyst Formation in polycystic Kidney Disease. J. Clin. Invest. 1998;101:935-939.

5. Sweeney WE Jr., Hamahira K, Sweeney J, García-Gatrell M, Frost P et al. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int. 2003; 64:1310-1319.

6. Wilson SM, Amsler K, Hyink DP, Li X, Lu W et al. Inhibition of HER-2(neu/ ErbB2) restores normal function and structure to polycystic kidney disease (PKD) epithelia. Biochimica et Biophysica Acta(BBA) 2006; 1762: 647-655.

7. Sweeney WE Jr, Chen Y, Nakanish K. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000;57:33–40.

8. Fernández A, Pérez R, Macías A, Velandia A, Alvárez I, Ramos M et al. Generation and characterization of anti-EGFR antibodies. Interferon y Biotecnología 1989; 6:289-98.

9. Fernandez A, Spitzer E, Pérez R, Boehmer FD, Eckert K, Zschiesche W et al. A new monoclonal antibody for detection of the EGF-R in Western Blot and paraffin embedded tissue sections. J Cell Biochem 1992; 49: 157-65.

10. Viloria-Petit A, Rengifo-Calzado E. Antiepidermal growth factor receptor antibody: Immunonohistochemistry. In: Handbook of immunohistochemistry and in situ hybridization oh human carcinomas. M.A. Hayat ed, vol.3, Elsevier Academic Press, 2005; 8:79-101.

11. Cedeño M, Rengifo CE, Rengifo Calzado E, Romero Y, Rodriguez T. Immunohistochemical Evaluation of H-R3 a Novel Humanized Monoclonal Antibody That Neutralizes the EGF-receptor. Appl Immunohistochem Mol Morpho 2007;15(2).

12. Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 1997; 8:1560.

13. Bisceglia M, Galliani CA, Senger C, Srallone C, Sessa A. Renal cystic diseases: A review. Adv Anat Pathol. 2006;13:26-56.

14. Ramírez AE, Fernández C, Narváez D, Teneud L. Expresión del receptor del factor de crecimiento epidérmico en biopsias renales de pacientes con nefronoptisis del adolescente. Nefrologia 2010; 30(5):518-21.

15. Mendelsohn J, Baselga J. Status of epidermal growth receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21(14):2787-2799.

16. Belibi FA, Edelstein CL. Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs. 2010 March ; 19(3): 315–328.

17. Crombet T, Torres O, Neninger E, Catala M, Rodríguez N, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biotherapy and Radiopharmaceuticals 2003; 16 (1):93-101.

18. Dell KM, Nemo R, Sweeney WE, Levin JI, Frost P, Avner ED. A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease. Kidney Int. 2001; 60:1240–1248.

19. Discafani CM, Carrol M, Floyd MB Jr, Hollander IJ, Husain Z, Johnson BD, et al. An irreversible inhibitor of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]- 2-butynamide (CL-387,785). Biochem Pharm 1999; 57:917–925.

20. Sweeney WE, Jr, Chen Y, Nakanish K et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000; 57:33–40.